Founding of Zhongshan Hospital
Named in memory of Sun Yat-sen, the hospital established a tradition of general hospital care and medical teaching that continues today.
Affiliated with Fudan UniversityZhongshan Hospital
Second nationally for general surgery and cardiovascular reputation, with innovation in liver cancer and interventional medicine.
Founded in 1937, Zhongshan Hospital ranked second in both general surgery and cardiovascular medicine in the 2023 Fudan National Specialty Reputation Rankings. Its Liver Cancer Institute twice received the National Science and Technology Progress First Prize for early diagnosis and treatment of small liver cancers and research on metastatic models. Coronary diagnosis, stents and valve interventions continue to generate original techniques. In 2022, China's first comprehensive National Medical Center construction project began here.
Shanghai, China
Early liver cancer care and cardiac intervention: a continuing tradition of Chinese innovation.
The liver cancer team, established in 1969, advanced the field through small liver cancer care and recurrence and metastasis research. The cardiovascular team improved interventions through intravascular ultrasound, retrograde guidewires and Chinese-developed coronary stents. Both strands connect basic research, clinical technology and national platforms.
National specialty reputation, successive generations of liver cancer research and original interventional devices together define Zhongshan's expertise.
National specialty reputation and national platforms
2023 Fudan National Specialty Reputation Rankings · Published in November 2024
General surgeryNo. 2
2023 national specialty reputation
Cardiovascular medicineNo. 2
2023 national specialty reputation
Comprehensive National Medical CenterFirst construction project
Launched in 2022 · China's first comprehensive center construction project
The ranking category is general surgery; liver surgery is not listed separately in this ranking.
Comprehensive National Medical Center construction project
Launched in 2022 as China's first comprehensive National Medical Center construction project, it brings together clinical medicine, research and technology translation resources to advance key diagnostic and treatment innovations.
Two National Science and Technology Progress First Prizes for liver cancer research
Research on the diagnosis and treatment of small liver cancers and highly metastatic human liver cancer models received the 1985 and 2006 National Science and Technology Progress First Prizes, respectively.
National Clinical Research Center for Radiology and Therapy
Formally launched in 2020, the center focuses on cardiac, vascular and tumor interventions, connecting device innovation, clinical research and collaborative networks.
The liver cancer research team's beginnings
Tang Zhaoyou, Yu Yeqin and colleagues formed an oncology group that became the foundation of Fudan University's Liver Cancer Institute.
Two National First Prizes for liver cancer research
Early diagnosis and treatment, and research on metastasis, became two enduring areas of original contribution.
Launch of the comprehensive National Medical Center project
China's first comprehensive center construction project began, advancing innovation in clinical care and medical technology.
Leading specialties,
built on medical achievements.
Explore Zhongshan Hospital's contributions in each field, from specialty standing to notable achievements, and the conditions this expertise supports.
Two National Science and Technology Progress First Prizes
1985 and 2006 · Major achievements of the Liver Cancer Institute
Zhongshan's liver cancer research began in 1969. Tang Zhaoyou and colleagues established approaches to early diagnosis and treatment of small liver cancers, then advanced research on recurrence and metastasis. Fan Jia, Zhou Jian and others continued to develop complex liver resection, molecular testing and combined treatment.
Systematic research on early diagnosis and treatment of small liver cancers
1985 National Science and Technology Progress First PrizeTang Zhaoyou and colleagues studied subclinical and small liver cancers, shifting care from managing advanced disease toward early detection and surgical treatment.
Establishing a highly metastatic human liver cancer model system
2006 National Science and Technology Progress First PrizeThe team developed highly metastatic human liver cancer models for metastasis research, bringing the clinical problem of recurrence into the laboratory and providing a basis for subsequent mechanism and treatment studies.
No. 2 nationally for general surgery reputation
General surgery's position in the 2023 Fudan rankings; liver surgery is the related field highlighted on this page.
Complex resection and perioperative research
Subsequent research covers portal vein tumor thrombus, complex liver resection, neoadjuvant and adjuvant treatment, forming a basis for collaboration between surgery and systemic therapy.
What conditions can this expertise help address?
For hepatocellular carcinoma and complex or recurrent liver cancer, the team can discuss resection, combined treatment and recurrence management in light of disease extent, liver function, vascular invasion and prior treatment.
No. 2 nationally for specialty reputation
2023 Fudan National Specialty Reputation Rankings · Cardiovascular Medicine
Zhongshan's cardiovascular team has contributed to coronary imaging diagnosis, interventions for complex occlusions, and Chinese-developed stents and valve devices, bringing clinical challenges together with device innovation.
Innovation in intravascular ultrasound and complex coronary intervention
The myocardial bridge half-moon sign · Retrograde guidewire techniquesGe Junbo's team identified an intravascular ultrasound feature of myocardial bridging and pioneered retrograde guidewire and supporting techniques for complex chronic total coronary occlusions.
National award for biodegradable-coated coronary stents
2011 National Technological Invention Second PrizeGe Junbo's research group developed a new biodegradable-coated coronary drug-eluting stent, advancing domestic device research and clinical translation.
National Clinical Research Center for Radiology and Therapy
Cardiovascular intervention is a major area of the center's technological innovation and clinical evidence-based research.
Structural heart disease and pulmonary vascular teams
Research and specialist collaboration involving TAVR, mitral valve intervention and pulmonary arterial hypertension.
What conditions can this expertise help address?
Coronary artery disease, aortic stenosis, mitral regurgitation and pulmonary arterial hypertension require the appropriate teams. Complete cardiac imaging, prior intervention records and medication information help inform discussion of specific treatment approaches.
Meet the specialists
through their achievements.
Discover the specialists' contributions and the conditions and treatments they focus on.
Showing 2 representative specialists
Fan Jia
Liver surgery
Chief physician, professor and member of the Chinese Academy of Sciences
Member of the Chinese Academy of Sciences · Leading expert in national award-winning liver cancer projects
Ask about this doctorTwice awarded the National Science and Technology Progress Second Prize for work on liver cancer tumor thrombus and postoperative recurrence
Fan Jia combines complex liver cancer surgery with research on vascular invasion, recurrence and metastasis, with long-standing work in clinical innovation and molecular mechanisms.
National award for combined treatment of portal vein tumor thrombus
Research into mechanisms and combined treatment techniques for liver cancer with portal vein tumor thrombus received the 2008 National Science and Technology Progress Second Prize.
A further national award for postoperative recurrence and metastasis research
He led a team studying prevention, treatment and key mechanisms of liver cancer recurrence and metastasis after liver transplantation, receiving the 2012 National Science and Technology Progress Second Prize, presented in 2013.
Conditions and treatment expertise
- Complex liver cancer surgery
- Assessment of surgery and combined treatment for complex liver cancer involving vascular invasion, portal vein tumor thrombus and related conditions.
- Liver cancer recurrence and metastasis
- Assessment of liver cancer recurring after prior treatment, along with perioperative and postoperative management questions.
Ge Junbo
Cardiology
Professor and member of the Chinese Academy of Sciences
Member of the Chinese Academy of Sciences · First-ranked contributor to a National Technological Invention Second Prize
Ask about this doctorFirst-ranked contributor to a National Technological Invention Second Prize for developing Chinese coronary stents
Ge Junbo's original research in coronary artery disease diagnosis and intervention connects intravascular imaging, guidewire techniques and device development, and extends to minimally invasive valve interventions.
National award for a Chinese-developed biodegradable-coated stent
He received the 2011 National Technological Invention Second Prize as the first-ranked contributor to the development of a new biodegradable-coated coronary drug-eluting stent.
Pioneering retrograde guidewire and supporting techniques
He developed interventions for chronic total coronary occlusions and identified the intravascular ultrasound half-moon sign of myocardial bridging, making internationally influential diagnostic and technical contributions.
Conditions and treatment expertise
- Coronary artery disease and complex coronary lesions
- Assessment for coronary intervention, including complex lesions such as chronic total occlusions and diagnosis involving intravascular imaging.
- Valve interventions
- Research and treatment assessment for structural heart disease, including mitral regurgitation and transapical mitral valve clipping techniques.
These profiles describe professional expertise and notable experience. The doctor, campus and appointment time are confirmed when arranging care.
Want to learn about Zhongshan Hospital?
Contact us directly.
Tell eastmedgo about the specialty, doctor or care question that matters to you, through WhatsApp or email.
Initial service inquiries are free. Medical assessments and treatment recommendations are provided by the receiving hospital and doctors.
Related reading
Medical guides related to this hospital’s specialties.
Liver surgery
HCC resection or ablation: why a Shanghai review starts with liver reserve
Compare the questions behind liver resection and ablation for localized HCC, including liver reserve, tumour position and a practical Shanghai assessment plan.
Read articleCan recurrent liver cancer be treated again? Reassessing options in Shanghai
After HCC recurrence, find out when repeat surgery or ablation remains possible, what other treatments may help, and how Shanghai teams can review the next step.
Read article
